News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
The Tufts Center for the Study of Drug Development is out with a new study claiming that the average cost of bringing a new drug to market is around $2.6bn, though some are saying that number seems inflated.
UK researchers working with GSK say a newly identified immune cell communication mechanism could explain why some drugs don’t work and drive development of smaller, large molecule meds.
Single-use continues to be adopted by the bioprocessing industry, but drugmakers are still hesitant to use disposable chromatography systems, says EMD Millipore.
Novartis has funded a company which will use emerging CRISPR-Cas gene editing technology for preclinical and clinical drug development.